<DOC>
	<DOCNO>NCT00011414</DOCNO>
	<brief_summary>This study evaluate tolerance effect tariquidar , give combination one three anticancer drug , treat solid tumor . Tariquidar work block pump cancer cell . The pump cell prevents anticancer drug accumulate call Pgp ( P-glycoprotein ) . Researchers hope see whether cancer-fighting drug stay cell longer . Patients age 2 18 solid tumor may eligible study . Tariquidar infuse intravenously ( IV ) 30 minute , give every 21 28 day , one drug kill cancer cell . Patients examine doctor least weekly treatment routine blood test twice weekly . They receive one follow drug tariquidar : doxorubicin ( Adriamycin ) , vinorelbine ( Navelbine ) , docetaxel ( Taxotere ) . At first treatment cycle , baseline Sestamibi scan treatment second one immediately drug administration . If patient receive tariquidar doxorubicin , tariquidar give alone . Then 48 72 hour later , second dose give , follow doxorubicin IV 15 minute . Dexrazoxane , decrease damage effect doxorubicin heart , also give IV 15 minute . Granulocyte colony stimulate factor ( G-CSF ) inject daily 48 hour doxorubicin , alleviate doxorubicin effect white blood cell . If patient receive tariquidar vinorelbine , tariquidar give alone . Then 48 72 hour later , second dose give , immediately follow vinorelbine IV 10 minute ; 1 week later , tariquidar give , immediately follow vinorelbine IV 10 minute . G-CSF give daily . If patient receive tariquidar docetaxel , tariquidar give alone . Then 48 72 hour later , second dose give , follow docetaxel IV 60 minute . Drugs prevent allergic reaction give docetaxel dose . G-CSF give daily . Tariquidar may affect blood pressure infusion , reduction normal blood cell , gastrointestinal problem , allergic reaction . The radioactive Sestamibi cause headache , chest pain , nausea . Radiation use study approve involve slightly great minimal risk adult acceptable risk child . This radiation consider necessary obtain information desire . One possible effect slight increase risk cancer . This study may may direct benefit participant . However , knowledge gain may benefit people cancer future .</brief_summary>
	<brief_title>Phase I Trial Tariquidar ( XR9576 ) Combination With Doxorubicin , Vinorelbine , Docetaxel Pediatric Patients With Solid Tumors</brief_title>
	<detailed_description>Background : - Pgp 170 kDa plasma membrane glycoprotein function non-specific energy-dependent drug efflux pump . Pgp express variety normal human tissue , renal proximal tubule , capillary endothelial cell comprise blood-brain barrier , epithelial cell line bile canaliculus , bone marrow stem cell , peripherial blood mononuclear cell . - Pgp over-expression tumor cell result multidrug resistance phenotype prevent intracellular accumulation variety chemotherapeutic agent , include anthracyclines , taxanes , vinca alkyloids , epipodophyllotoxins . Inhibition Pgp may partially reverse multidrug resistance increase intracellular drug accumulation tumor cell . - Tariquidar ( XR9576 ) specific Pgp inhibitor block Pgp function 24 hour single dose without significant toxicity animal human . - In adult , tariquidar combination doxorubicin , paxlitaxel , vinorelbine well tolerate , minor alteration clearance drug exposure ( area concentration time curve , AUC ) anticancer drug observe . Objectives : - Study tolerance toxicity profile tariquidar three dose level combination one three anticancer drug ( doxorubicin , docetaxel , vinorelbine ) pediatric patient refractory solid tumor include brain tumor . - Define maximum tolerate dose tariquidar child dose-limiting toxicity observe dos less equal 2 mg/kg . - Study pharmacokinetics tariquidar alone combination doxorubicin , docetaxel vinorelbine pediatric patient . - Study pharmacodynamics ( effect Pgp function ) tariquidar ex vivo peripheral blood mononuclear cell ( CD56+ ) rhodamine uptake assay vivo tissue tumor ( 99m ) Tc-sestamibi scan . - Study alteration acute toxicity pharmacokinetic profile doxorubicin , vinorelbine docetaxel administer combination tariquidar . - When possible , assess Pgp expression tumor specimens immunohistochemistry compare immunohistochemisty result vivo Pgp functional study ( 99m ) Tc-sestamibi scan ) . Eligibility : -Children adolescent ( great equal 2 year less equal 18 year age ) histologically confirm relapsed refractory solid tumor measureable evaluable . Design : - Tariquidar administer alone combination doxorubicin , vinorelbine , doctaxel . Tariquidar dose level 1 , 1.5 , 2 mg/kg . Intrapatient dose escalation tariquidar permit . - Detailed pharmacokinetic pharmacodynamic study perform cycle 1 . - The trial follow standard phase 1 design 3 6 patient per dose level . At recommedmed dose tariquidar , 6 patient enrol cytotoxic agent . Up 36 patient enter trial .</detailed_description>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>INCLUSION CRITERIA : Age : Patients must great equal 2 less equal 18 year age . Diagnosis : Histologically confirm solid tumor may include limited rhabdomyosarcoma soft tissue sarcoma , Ewing 's sarcoma family tumor , osteosarcoma , neuroblastoma , Wilms ' tumor , hepatic tumor , germ cell tumor , primary brain tumor . In patient brain stem optic glioma requirement histological confirmation may waive . Measurable/Evaluable Disease : Patients must measurable evaluable tumor . Prior Therapy : The patient 's cancer must relapse failed respond frontline curative therapy must potentially curative treatment option available . Curative therapy may include surgery , radiation therapy , chemotherapy , combination modality . For patient receive doxorubicin study , patient must last dose radiation therapy least four week prior study entry ; For patient receive docetaxel vinorelbine , patient must last dose extensive radiation ( craneospinal 50 percent pelvis ) least 4 week prior study entry last dose limited field radiation ( local ) least 2 week prior study entry . Patients must last dose chemotherapy least 21 day prior study entry ( 28 day nitrosoureas ) , last dose investigational cancer therapy least 30 day prior study entry . Patients must recover toxic effect prior therapy entry onto trial . Patients brain tumor must stable taper dose corticosteriods 7 day prior baseline scan perform purpose assess response therapy study . Patients colony stimulating factor GCSF , GMCSF , erythropoietin , IL11 least 72 hour prior study entry . Lifetime cumulative dose anthracycline : Restrictions prior cumulative dose anthracylines apply patient receive doxorubicin combination tariquidar . The lifetime cumulative dose anthracycline must less equal 300 mg/m ( 2 ) patient receive doxorubicin combination tariquidar , anthracycline administer bolus injection without cardioprotectant ( e.g. , dexrazoxane ) OR patient mediastinal radiation . The lifetime cumulative dose anthracycline must less equal 400 mg/m ( 2 ) , anthracycline administer continuous infusion cardioprotectant patient mediastinal radiation . Performance Status : Patients ECOG performance status 0,1 , 2 . Patients unable walk paralysis weakness , wheelchair consider ambulatory purpose calculate performance score . Hematologic Function : Patients must adequate bone marrow function , define peripheral absolute granulocyte count great equal 1,500/microL , hemoglobin great equal 8 gm/dL , platelet count great equal 100,000/microL . Hepatic Function : Patients must adequate liver function , define bilirubin within normal limit , SGPT ( ALT ) less 2x upper limit normal . Renal Function : Patients must ageadjusted normal serum creatinine OR creatinine clearance great equal 60 mL/min/1.73 ( 2 ) . Cardiac Function : Patients receive doxorubicin must normal cardiac ejection fraction echocardiogram . An echocardiogram need perform patient receive docetaxel vinorelbine . Informed Consent : All patient legal guardian ( patient le 18 year old ) must sign document inform consent indicate understanding investigational nature risk study protocol relate study perform . ( This include routine laboratory test image study require establish eligibility ) . Durable Power Attorney ( DPA ) : Patients brain tumor great equal 18 year age offer opportunity assign DPA another person make decision medical care become incapacitated cognitively impaired . EXCLUSION CRITERIA : Clinically significant unrelated systemic illness , serious infection , hepatic , renal organ dysfunction , judgement Principle Associate Investigator would compromise patient 's ability tolerate agent trial likely interfere study procedure result . Patients history bone marrow transplantation within previous 4 month extensive radiotherapy ( craniospinal radiation , total body radiation , radiation half pelvis ) within previous 4 month . Pregnant breast feeding female exclude tariquidar combination cytotoxic drug may harmful develop fetus nursing child .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 13, 2016</verification_date>
	<keyword>Drug Resistance</keyword>
	<keyword>PEDIATRIC SOLID TUMORS</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>p-glycoprotien</keyword>
	<keyword>Brain Tumors</keyword>
	<keyword>Childhood Cancer</keyword>
	<keyword>Brain Tumor</keyword>
</DOC>